Attached files

file filename
EX-99.2 - EXHIBIT 99.2 - Aevi Genomic Medicine, Inc.v332330_ex99-2.htm
EX-99.1 - EXHIBIT 99.1 - Aevi Genomic Medicine, Inc.v332330_ex99-1.htm






Washington, D.C. 20549




Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


January 17, 2013 (January 17, 2013)
Date of Report (Date of earliest event reported)


(Exact name of registrant as specified in its charter)


Delaware 1-35112 98-0217544
(State or other jurisdiction of
incorporation or organization)
(Commission File Number) (I.R.S. Employer
Identification No.)


555 California Street, Suite 365

San Francisco, California 94104 

(Address of principal executive offices, zip code)


(415) 568-2245
(Registrant’s telephone number, including area code)


Not Applicable
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 8.01.      Other Events.


Medgenics, Inc. is filing the company overview attached as Exhibit 99.1 for the purpose of updating certain aspects of its publicly disclosed descriptions of its business, and the risk factors attached as Exhibit 99.2 for the purpose of updating the risk factor disclosure contained in its public filings, including those discussed under the caption “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2011 and its Quarterly Report on Form 10-Q for the three month period ended September 30, 2012, which were filed with the Securities and Exchange Commission on March 6, 2012 and November 14, 2012, respectively.


Item 9.01.       Financial Statements and Exhibits.


(d) Exhibits. The following exhibit is furnished herewith:


Exhibit No.   Description
99.1   Company Overview
99.2   Risk Factors






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  By: /s/ Phyllis K. Bellin
    Name: Phyllis K. Bellin
    Title: Vice President – Administration


Date:    January 17, 2013